The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes
Semaglutide may adversely affect lumbar fusion outcomes and necessitate additional surgery, possibly secondary to its systemic effects on bone metabolism and weight loss patterns. Further research into optimal drug formulation, dosage, and weight loss protocols will be required before mainstream use.
Authors
- Elie Massaad (ORCID: https://orcid.org/0000-0003-4883-914X)
- Ryan Wang (ORCID: https://orcid.org/0000-0002-9681-4695)
- Owoicho Adogwa
- John H. Shin (ORCID: https://orcid.org/0000-0001-7490-8108)
- Aladine A. Elsamadicy (ORCID: https://orcid.org/0000-0002-7658-6461)
- Syed Khalid (ORCID: https://orcid.org/0000-0003-4710-1688)
- Pranav Mirpuri (ORCID: https://orcid.org/0000-0001-5860-610X)
Institutions
- University of Minnesota (US)
- Rosalind Franklin University of Medicine and Science (US)
- Yale University (US)
- University of Illinois Chicago (US)
- Massachusetts General Hospital (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Clinical Neurology and Neurosurgery
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.clineuro.2025.108952
- Citations
- 2
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79